Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: scope who wrote (12271)	7/29/1998 9:35:00 PM
From: Zebra 365	Read Replies (3) \| Respond to of 23519

Another former Vivus person in a new direction: SEQUUS Pharmaceuticals Names Top Executives to Round-Out Senior Management Team Joseph J. Vallner Promoted to Chief Operating Officer; John P. Richard Appointed Executive Vice President for Business Development MENLO PARK, Calif., July 29 /PRNewswire/ -- SEQUUS Pharmaceuticals, Inc. (Nasdaq: SEQU) today announced the appointment of John P. Richard as Executive Vice President for Business Development and the promotion of Joseph J. Vallner, Ph.D. to Chief Operating Officer. Mr. Richard joins SEQUUS from VIVUS, Inc. where he served as Vice President, Corporate Development with responsibility for new business development and licensing. Dr. Vallner will continue to be responsible for directing the day-to-day operations of the Company. "These appointments mark the culmination of an intensive 12-month effort to coalesce an effective and experienced senior management team as we move forward into our next stage of growth," said Dr. I. Craig Henderson, Chairman and CEO of SEQUUS. "The appointment of Joe Vallner to COO is a vote of confidence by the Board and myself that he will continue his superb job of managing the overall operations of SEQUUS with the same success that he has since August, 1997." Dr. Henderson added, "John Richard's expertise in forming business alliances and partnerships within our industry should prove fruitful in enriching the value of our patented STEALTH(R) technology across the board -- through research collaborations, in-licensing, co-marketing or co-development efforts, and further STEALTH out-licensing opportunities." "I'm excited by the opportunities afforded by SEQUUS," said Mr. Richard. "The Company's proven and unique STEALTH drug delivery technology platform provides a substantial foundation for multiple partnering opportunities in a broad range of applications including additional oncology drugs, gene therapy, antisense, anti-infectives, angiogenesis and radiosensitizers." Prior to joining VIVUS, Mr. Richard was Senior Vice President, Business Development, with Genome Therapeutics Corporation of Waltham, Massachusetts, where he was responsible for a comprehensive program to commercialize the company's genomic research, which resulted in $130 million in corporate alliances with major pharmaceutical companies (1990 to 1997). Previously, Mr. Richard was founder and president of IMPATH Laboratories, the leading cancer pathology reference laboratory in the United States (1987 to 1990). Mr. Richard received his M.B.A. from Harvard University. Dr. Vallner joined SEQUUS in 1992 and has played a key role in the development and approval of DOXIL(R) and AMPHOTEC(R), and in expanding the pipeline potential of the Company's proprietary STEALTH technology platform. Prior to joining SEQUUS, Dr. Vallner was Director, Corporate Technology Transfer, with Syntex Corporation, where he was responsible for various pharmaceutical development functions ranging from drug design and development to regulatory filings with the FDA for line extensions and new chemical entities (1986 to 1992). Dr. Vallner received his Ph.D. in Pharmaceutics from the University of Wisconsin. SEQUUS is an integrated pharmaceutical company revolutionizing therapies for cancer and other diseases utilizing advanced drug delivery technologies. SOURCE SEQUUS Pharmaceuticals, Inc. CO: SEQUUS Pharmaceuticals, Inc. PS: I'm not posting on a Moron thread Jack, couldn't find it. Been busy shorting LCOS lately, not a bad hobby while waiting for VVUS to do something. Zebra